BRPI0416870A - composições anticáncer sinergìticas - Google Patents

composições anticáncer sinergìticas

Info

Publication number
BRPI0416870A
BRPI0416870A BRPI0416870-4A BRPI0416870A BRPI0416870A BR PI0416870 A BRPI0416870 A BR PI0416870A BR PI0416870 A BRPI0416870 A BR PI0416870A BR PI0416870 A BRPI0416870 A BR PI0416870A
Authority
BR
Brazil
Prior art keywords
compositions
antineoplastic
synergistically
synergistic
combinations
Prior art date
Application number
BRPI0416870-4A
Other languages
English (en)
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of BRPI0416870A publication Critical patent/BRPI0416870A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES ANTICáNCER SINERGìTICAS". A presente invenção refere-se a composições utilizáveis em tratamento de câncer. As composições incluem uma combinação sinergística de um oxidante mitocondrial ligando tiol antineoplásico com um agente de ligação de ácido nucléico antineoplásico, um análogo de base antimetabolita antineoplásico, ou docetaxel. Também são providos os métodos de teste dos efeitos sinergísticos das combinações e métodos de tratamento de câncer usando as combinações sinergísticas.
BRPI0416870-4A 2003-12-08 2004-12-08 composições anticáncer sinergìticas BRPI0416870A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52818103P 2003-12-08 2003-12-08
PCT/US2004/041093 WO2005055952A2 (en) 2003-12-08 2004-12-08 Synergistic anti-cancer compositions

Publications (1)

Publication Number Publication Date
BRPI0416870A true BRPI0416870A (pt) 2007-01-30

Family

ID=34676825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416870-4A BRPI0416870A (pt) 2003-12-08 2004-12-08 composições anticáncer sinergìticas

Country Status (13)

Country Link
US (3) US20050176696A1 (pt)
EP (1) EP1691801A4 (pt)
JP (1) JP2007513202A (pt)
KR (1) KR20060103947A (pt)
CN (1) CN1889943A (pt)
AU (1) AU2004296863B2 (pt)
BR (1) BRPI0416870A (pt)
CA (1) CA2548491A1 (pt)
IL (1) IL175665A0 (pt)
MX (1) MXPA06006291A (pt)
NZ (1) NZ547252A (pt)
WO (1) WO2005055952A2 (pt)
ZA (1) ZA200604579B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063778A2 (en) * 2006-10-12 2008-05-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic corticosteriods for the treatment of cancer
EP2154971B1 (en) * 2007-05-15 2011-12-28 Piramal Life Sciences Limited A synergistic pharmaceutical combination for the treatment of cancer
CN101903029B (zh) * 2007-11-02 2012-09-26 Zio医药肿瘤学公司 使用有机砷化物的联合治疗
TWI492759B (zh) * 2008-03-05 2015-07-21 Otsuka Pharma Co Ltd 膽甾烷醇衍生物之併用用途
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
EP2833883A4 (en) * 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
CN111053768B (zh) 2013-07-12 2023-12-12 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
AU2015264102C1 (en) * 2014-05-23 2020-10-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
CN104267188B (zh) * 2014-08-28 2015-12-30 汪建平 针对msk1基因的相关制剂在制备5-fu耐药性检测试剂及5-fu耐药逆转剂方面的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727046A (en) * 1986-07-16 1988-02-23 Fairchild Semiconductor Corporation Method of fabricating high performance BiCMOS structures having poly emitters and silicided bases
DE3825667A1 (de) * 1988-07-28 1990-03-15 Boehringer Mannheim Gmbh Verwendung von imexon als immunsuppressivum
US5369119A (en) * 1988-07-28 1994-11-29 Boehringer Mannheim Gmbh Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
DE3841879A1 (de) * 1988-12-13 1990-06-21 Boehringer Mannheim Gmbh Neue imidazolidin-derivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6005097A (en) * 1996-06-14 1999-12-21 Vion Pharmaceuticals, Inc. Processes for high-yield diastereoselective synthesis of dideoxynucleosides
US5869676A (en) * 1997-05-15 1999-02-09 Vion Pharmaceuticals, Inc. Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP
US5767134A (en) * 1997-05-15 1998-06-16 Vion Pharmaceuticals, Inc. Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
DE69819192T2 (de) * 1997-06-27 2004-06-09 Amplimed, Inc., Tucson Neue cyanoaziridine zur behandlung von krebs
AU1172502A (en) * 2000-10-13 2002-04-22 Vion Pharmaceuticals Inc Modified prodrug forms of ap/amp
US20030129222A1 (en) * 2000-11-21 2003-07-10 Gabriel Lopez-Berestein Liposomal imexon
CA2431947A1 (en) * 2000-11-21 2002-05-30 Gabriel Lopez-Berestein Composition comprising an imexon or derivatives thereof and lipids
US6476236B1 (en) * 2001-11-26 2002-11-05 The Arizona Board Of Regents Synthesis of 2-cyanoaziridine-1-carboxamide

Also Published As

Publication number Publication date
AU2004296863B2 (en) 2008-12-11
AU2004296863A1 (en) 2005-06-23
WO2005055952A2 (en) 2005-06-23
US20080153891A1 (en) 2008-06-26
ZA200604579B (en) 2007-10-31
KR20060103947A (ko) 2006-10-04
MXPA06006291A (es) 2006-08-23
WO2005055952A3 (en) 2005-12-15
IL175665A0 (en) 2008-04-13
NZ547252A (en) 2008-09-26
EP1691801A2 (en) 2006-08-23
EP1691801A4 (en) 2009-12-09
US20080146653A1 (en) 2008-06-19
JP2007513202A (ja) 2007-05-24
CN1889943A (zh) 2007-01-03
CA2548491A1 (en) 2005-06-23
US20050176696A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
BRPI0622054B8 (pt) composto e composição farmacêutica
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
WO2004050033A3 (en) Method of treating cancers
BRPI0518281A2 (pt) inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
PA8580201A1 (es) Terapia de combinacion para enfermedades hiperproliferativas
BRPI0512535A (pt) compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
EA200701793A1 (ru) Состоящие из наночастиц композиции доцетаксела и его аналогов
CR9987A (es) Compuestos de lactama y métodos de uso de los mismos
BR0007430A (pt) Composição tópica compreendendo n-acetilaminoácidos ou n-acetilaldosaminas
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
BR0206046A (pt) Usos de uma combinação e de sapogenina protopanaxadiol ou sapogenina protopanaxatriol, e, composição farmacêutica
EP1392328A4 (en) Cancer therapy
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
BRPI0507895A (pt) composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório
BRPI0416870A (pt) composições anticáncer sinergìticas
BR0314142A (pt) Composição administrável oralmente para melhoria da qualidade do cabelo ou da pele
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.